Abstract

Inflammatory dilated cardiomyopathy (DCMi) is a syndrome, not an etiological disease entity. The infective etiology and the immunopathology can be best determined through endomyocardial biopsy with a complete work-up by light microscopy, immunohistology, and polymerase chain reaction for microbial agents. This review focuses on the methodological advances in diagnosis in the past few years and exemplifies the importance of an etiology-orientated treatment in different case scenarios. In fulminant nonviral myocarditis, immunosuppressive treatment together with hemodynamic stabilization of the patient via mechanical circulatory support (e.g., microaxial pumps, extracorporeal membrane oxygenation, left ventricular assist device) can be life-saving. For viral inflammatory cardiomyopathy, intravenous immunoglobulin treatment can resolve inflammation and often eradicate the virus.

Highlights

  • In immunocompetent patients, herpesviruses including EBV and human herpesvirus 6 (HHV6) infections rarely induce cardiac symptoms

  • The infective etiology and the immunopathology can be best determined through endomyocardial biopsy with a complete work-up by light microscopy, immunohistology, and polymerase chain reaction for microbial agents

  • Prevalence rates for HHV6 genomes detected in patients with myocarditis or DCM ranged from 8 to 20% and for EBV genomes from 0 to 8%

Read more

Summary

Introduction

Herpesviruses including EBV and HHV6 infections rarely induce cardiac symptoms. Intravenous immunoglobulin treatment can resolve inflammation and often eradicate the virus. Keywords Myocarditis · Endomyocardial biopsy · Immunohistology · Intravenous immunoglobulins · Immunosuppressive therapy In the larger series of patients with inflammatory heart diseases, analyses for HHV6 and EBV were always included.

Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call